Upstate Active Clinical Trials
Study Title:Roche WN39658: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,
PARALLEL-GROUP, EFFICACY, AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH
PRODROMAL TO MILD ALZHEIMER’S DISEASE (GRADUATE II)
What is the purpose of the study?The purpose of this study is to evaluate the effects, good or bad, of gantenerumab versus placebo (an inactive substance that looks like gantenerumab) on you and your memory problems.
Upstate Institutional Review Board (IRB) Number:1118966
Study Phase:Phase III
Patient Age Group:Adults
Principal Investigator:Sharon A Brangman
Who can I contact for more information?
Name: Linda L Spillett, CCRP